Biomedical subjects

Anders Westermark

Publications and source records attributed to Anders Westermark.

4 recordsLinked to original sources

PubMed2006

Three-dimensional technology and bone morphogenetic protein in frontal bone reconstruction.

Osteoinductive bone morphogenetic proteins (BMPs) may be used in humans to facilitate healing of bony defects. The effect of different BMPs is, as with many other growth factors, highly dependent on the delivery vehicle. Bovine type I collagen is currently used in the clinical setting as a carrier and has been approved in several countries for human use. Here, we report the reconstruction of a frontal bone defect using heparin together with bovine type I collagen, hyaluronic acid, and fibrin as vehicles for BMP-2. A bony structure was created on the back of the patient by treating the latissimus dorsi muscle with the growth factor. A polyamide mold was used as a template to achieve the desired shape. The bone structure was transplanted into the defect site via microsurgical techniques. Although the prefabricated bone was not large enough tocover the entire frontal defect, the reconstruction was completed by using an additional cranial implant.

Animals↗

PubMed2005

Three-dimensional osteotomy planning in maxillofacial surgery including soft tissue prediction.

Preoperative planning of complex osteotomies in craniomaxillofacial surgery, in conjunction with a surgeon's expertise, is essential for achieving an optimal result. However, the soft tissue changes that accompany facial bone movements cannot yet be accurately predicted. Bony tissue, because of its greater density, can be better predicted, but it alone does not account for the final aesthetic result. A new approach using not only three-dimensional (3-D) surface models of the patient's anatomy, but also a corresponding volumetric model, is discussed. This 3-D planning software was used in the treatment of 15 patients and was found to provide a good correlation between simulation and postoperative outcome.

Adipose Tissue↗

PubMed2004

Basic fibroblast growth factor (bFGF) in saliva and oral mucosa in patients with oral lichen planus: preliminary observations.

OBJECTIVE: Basic fibroblast growth factor (bFGF) is important for wound healing and tissue repair. This study measures the concentration of bFGF in oral lichen planus (OLP) affected mucosa and in the saliva of patients with OLP. STUDY DESIGN: Samples of saliva, OLP-affected mucosa, and clinically healthy mucosa were obtained from 11 patients. Control samples were obtained from healthy volunteers. The bFGF content of tissue samples and saliva was examined by ELISA. RESULTS: The mean bFGF concentration in saliva from OLP patients was 5.9 pg/mL, SD 2.9, compared with 0.3 pg/mL, SD 0.3, in the control group, (P>.01). The bFGF content in the OLP tissue was 90.6 microg/mg protein, SD 39.5, in clinically normal mucosa from OLP individuals it was 46.2 microg/mg protein, SD 12.0 (P=.02), and in the control group 46.2 microg/mg protein, SD 11.5 (P>.01). CONCLUSION: OLP-affected mucosa contained significant more bFGF than nonaffected mucosa in OLP and healthy mucosa in control group. There is no difference between nonaffected mucosa in OLP and control group. Saliva in OLP patients contained more bFGF than saliva in control patients.

Adult↗

PubMed2002

Basic fibroblast growth factor in human saliva decreases with aging.

OBJECTIVE: Basic fibroblast growth factor (bFGF) has significant properties in wound healing and tissue repair and is suggested to be of importance for the maintenance of mucosal integrity in the upper digestive tract. The purpose of the present study was to identify any age-dependent variations in the concentration of bFGF in human saliva. STUDY DESIGN: Nonprospective, cross-sectional pilot study. METHODS: The study was based on findings from 182 healthy volunteers with ages ranging from 4 to 97 years. Mixed saliva samples were obtained by drooling. The saliva concentration of bFGF was determined with a commercially available enzyme-linked immunosorbent assay kit. RESULTS: The mean saliva concentration of bFGF was 0.41 pg/mL with no gender differences. In persons aged 4 to 19 years, the mean concentration was 0.72 pg/mL; in those aged 20 to 65 years, 0.33 pg/mL; and in those aged 66 to 97 years, 0.005 pg/mL. These age-dependent differences were highly significant. In the youngest group the saliva concentration of bFGF varied more than in the other groups. CONCLUSIONS: The saliva concentration of bFGF varies with individual age, with the highest levels among young individuals, even levels during a mature phase of life, and low levels toward the end of the life cycle. This strongly suggests a physiological implication of bFGF in saliva.

Adolescent↗